🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⭐️PLEASE NOTE⭐️ Abstract 508: OASIS 4: Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy WILL BE INCLUDED in the RE RELEASE OF THIS POST of TOP #BreastCancer Abstracts to be presented at #ASCO25 Matteo Lambertini, MD PhD Evandro de Azambuja, MD, PhD

👉 Stay up to date with the latest evidence-based recommendations from the #ESMOGuidelines for the treatment of metastatic #breastcancer to optimise patient outcomes. Join this live discussion and submit your questions 🔗 ow.ly/qwpi50VX2bo

We started this Programme almost 10 years ago and it has been a success since then! Don't miss this unique opportunity to strength your skills in leadership and communication. @Teresa Amaral ESMO - Eur. Oncology #career #leadership #communication

The OncoAlert🚨 RoundUp DAY TWO #ASCO25 REGISTER HERE 👉 OncoAlert360.com OR buff.ly/p0O1gZ8 FOR A MORE COMPLETE VIEW of the TOP of DAY 2 of the congress Discussing:✅ ✅ASCENT-04/KEYNOTE #BreastCancer ✅VERITAC-2 in BreastCancer ✅INAVO120 in BreastCancer

SERENA-6 will be presented today at the Plenary Session of #ASCO25 and has just been published in the NEJM Acting on emerging ESR1 mutations prolongs patients' progression-free survival nejm.org/doi/full/10.10… OncoAlert

The #OncoAlertTOPTweet Day Two 🚨 #ASCO25 Post from OncoAlert AF Icro Meattini ASCENT-04 - sacituzumab govitecan plus pembrolizumab as a new standard for #BreastCancer with previously untreated PDL1+ TNBC Post OncoAlert #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD

Impressive 40.7 months mPFS with TDXd and pertuzumab! This may represents a new SOC as 1st line therapy for patients with HER2 positive MBC Sara Tolaney AstraZeneca Daiichi Sankyo US OncoAlert

Dear Colleagues at #ASCO25 An honor to Present our OncoAlert Faculty Sara Tolaney 🇺🇸 from Dana-Farber Who has just presented DESTINY-Breast09 T-DXd +pertuzumab vs taxane+trastuzumab+pertuzumab in FIRST Line Treatment of HER2+ advanced/metastatic #BreastCancer Matteo Lambertini, MD PhD

🫀 Cardiovascular toxicity is a growing concern in #breastcancer survivorship In our latest ESMO Open review, we outline strategies for prevention, early detection and management 🔗sciencedirect.com/science/articl… Evandro de Azambuja, MD, PhD Elisa Agostinetto OncoAlert

How does HER2+ ILC fare long-term? #ALTTO data ⬆️ CNS relapse risk in ILC vs NST (13.6% vs 5.0%; HR 3.14) – DFS & OS similar despite clinicopathologic differences – Importance of central histology review Poster BD135 | #ASCO25 – come by! OncoAlert

It was a true pleasure to present at the ASCO TECAG Lounge at #ASCO25 on the Keys to Success for an Early Career Oncologist! 🔑 💫 Thanks to Tobe for the excellent moderation and to the entire panel Mina S. Sedrak Muhamad Alhaj Moustafa, MD, MS Tim Brown, MD MSCE ASCO OncoAlert

Although derived from different cohorts, these results are in line with our findings published in JNCI (academic.oup.com/jnci/advance-a…) and underscore the need to discuss adjuvant CDK4/6 inhibitors on a case-by-case basis! OncoAlert

The elections for directors are open until June 10! Your vote truly matters and plays a vital role in shaping the future of our community. Join us by casting your vote and making a real difference! ESMO - Eur. Oncology FabriceAndre Andres Cervantes G Curigliano MD PhD Vote now: ow.ly/XX3W50VZQyL

RWE evidence supports the de-escalation APT strategy for stage I HER2+ early #breastcancer The 5-year rwDFS rate was 95.3% (92.7-98.1) and rwOS was 97.9% (96.299.7). Soraia Lobo-Martins Véronique Debien Elisa Agostinetto Flavia Jacobs et al! authors.elsevier.com/c/1lDZV5RAAoti…

Diversity in clinical trials: Maghreb pts have younger age and more aggressive BC but similar survival outcomes doi.org/10.1016/j.clbc… Chiara Dauccia Véronique Debien Soraia Lobo-Martins Elisa Agostinetto Luca Arecco, MD Diogo Martins Branco

New 📰: Q-TWiST Analysis to Assess Benefit-Risk of #SacituzumabGovitecan in Previously Treated Patients With Metastatic #TNBC. 👉pubmed.ncbi.nlm.nih.gov/40561376/ Aditya Bardia, MD Hope Rugo Mina S. Sedrak Sibylle Loibl Sara Tolaney Kevin Punie Kevin Kalinsky, MD, MS, FASCO Joyce O'Shaughnessy, MD Adam Brufsky

Deep learning-based quantification of TILs as a prognostic indicator in nasopharyngeal carcinoma: multicohort findings in ESMO Open. DL-assessed TILs strongly correlates with survival in NPC, better prediction than IHC. esmoopen.com/article/S2059-…

New in BreastCancerResearch - Multicenter study led by KarenVanBaelen of 2,098 pts w/ early ER+/HER2– lobular BC Over 50% had HER2-low tumors—associated with larger size, multifocality & worse DFS/OS vs HER2-0 Key insights for prognosis & treatment strategies OncoAlert

🆕review in press: Clinical challenges and proposed solutions for patients with invasive lobular breast cancer Christine Desmedt doi.org/10.1016/j.anno…